Pais / Región
Paises

Provincias / Departamentos
Colombia Colombia
Argentina Argentina
Canada Canada
Chile Chile
Ecuador Ecuador
España España
Guatemala Guatemala
Honduras Honduras
Mexico Mexico
Panama Panama
Paraguay Paraguay
United States United States
Uruguay Uruguay
Categorias / Industrias
Publication: 0000-00-00 00:00:00
United States SAM

FOR COVID-19: GENSCRIPT SEQUENCING

Process Number NOI-NIAID-2103176

USA

Dates:


Notice ID:

NOI-NIAID-2103176

Department/Ind. Agency:

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Sub-tier:

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Sub Command:

NATIONAL INSTITUTES OF HEALTH NIAID

Office:

NATIONAL INSTITUTES OF HEALTH NIAID

General Information:


All Dates/Times are:

(utc-05:00) eastern standard time, new york, usa

Updated Published Date:

(utc-05:00) eastern standard time, new york, usa

Original Published Date:

0000-00-00 00:00:00

Original Response Date:

dec 27, 2021 10:00 am est

Inactive Policy:

15 days after response date

Initiative:
  • None***--***

Classification:


Product Service Code:

q301 - medical- laboratory testing

NAICS Code:

541380 - testing laboratories

Description:


Original Set Aside:

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate with other than full and open competition basis with Genscript USA Incorporated, 860 Centennial Ave, Piscataway, NJ 08854. The mission of the NIH Vaccine Research Center (VRC) is to facilitate the development of vaccines against HIV-AIDS. Our goal is to develop immunogens that will elicit broadly neutralizing antibodies and will be used in vaccine design. One of the aims of the project is to obtain atomic level structures of the envelope glycoproteins that are the sole exterior target for neutralizing antibodies. Another aim is to develop neutralizing antibodies against HIV. Vaccine immunogens are custom designed at VRC and thus is not commercially available. The DNA plasmids for the designed vaccine immunogens and antibodies will be synthesized by a service provider in order to be expressed and purified at VRC for further characterization. We have been using Genscript for DNA synthesis services for this COVID-19 ongoing project, and it has proven to support our protocols in the development of vaccines for HIV and other viruses. Changing provider now will compromise the integrity of our data. No substitutions are accepted for this project. The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2103176) to Skye Duffner at skye.duffner@nih.gov, by 10:00 am eastern standard time, December 27, 2021. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Attachments / Links:


Document Size Updated date Download

Contact Information:


5601 FISHERS LANE, SUITE 3D11

BETHESDA , MD 20892

USA

Primary Point of Contacts:

Skye Duffner

Secondary Point of Contact:

Laura Grey